Fig. 1: Survival outcomes, genomic landscape, and correlation analysis of clinical parameters. | npj Precision Oncology

Fig. 1: Survival outcomes, genomic landscape, and correlation analysis of clinical parameters.

From: Comparative analysis of ctDNA monitoring strategies in advanced NSCLC with MET exon 14 skipping mutations treated with ensartinib

Fig. 1: Survival outcomes, genomic landscape, and correlation analysis of clinical parameters.

A Kaplan-Meier curves for progression free survival (PFS) and overall survival (OS) for the entire evaluable cohort (n = 30). B Waterfall plot depicting the distribution of somatic alterations detected in 29 patients. Genes are ordered by mutation frequency. Variant classification is indicated by color. C Correlation between tumor burden as calculated by the sum diameters of target lesion and the baseline variant allele frequency (VAF) of MET-specific alterations in MET ctDNA positive patients. D Correlation between tumor burden as calculated by the sum diameters of target lesion and the baseline mean VAF of pan-alterations.

Back to article page